BOA Biomedical (BOA) leverages platform technology developed at the Wyss Institute for Biologically Inspired Engineering at Harvard University to rapidly diagnose and treat infectious diseases.

 

BOA licensed the initial technology for this medical device in 2018 ad has been working on taking this from bench to bedside since. BOA’s products detect and clear pathogens and their toxins and can be used to diagnose and treat patients with new viruses for which there is little immunity, antimicrobial-resistant infections and sepsis. BOA’s goal is to save lives by accelerating diagnoses of infectious diseases and improving treatment outcomes as we enter an age of increasing pandemic threats that stress our healthcare systems and economies.